DUSP1 and colorectal carcinoma: Future efforts will focus on verifying these findings in larger patient cohorts, exploring combination therapies that target multiple oncogenic nodes, and determining whether modulating CEBPB–DUSP1 activity can meaningfully improve clinical outcomes for patients with advanced CRC.